Despite its potential, cancer proteomics faces several challenges:
Complexity of the Proteome: The human proteome is highly complex, with a wide dynamic range of protein concentrations, making it difficult to detect low-abundance proteins. Sample Heterogeneity: Tumors are heterogeneous, containing a mix of different cell types, which can complicate the interpretation of proteomic data. Technical Limitations: Current mass spectrometry techniques have limitations in terms of sensitivity, resolution, and throughput.
